ArticleFuture virology2018
Poliovirus containment risks and their management.
Article in Future virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.Expert review of vaccines · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
aimAssess risks related to breaches of poliovirus containment.
methodUsing a dynamic transmission model, we explore the variability among different populations in the vulnerability to poliovirus containment breaches as population immunity to transmission declines after oral poliovirus vaccine (OPV) cessation.
resultsAlthough using OPV instead of wild poliovirus (WPV) seed strains for inactivated poliovirus vaccine (IPV) production offers some expected risk reintroduction of live polioviruses from IPV manufacturing facilities, OPV seed strain releases may become a significant threat within 5-10 years of OPV cessation in areas most conducive to fecal-oral poliovirus transmission, regardless of IPV use.
conclusionsEfforts to quantify the risks demonstrate the challenges associated with understanding and managing relatively low-probability and high-consequence containment failure events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.